 |
10 Companies | 10 Products |
|
|
10 Products | |
667 Diseases | |
132 Trials |  |
5551 News |  |
| 12345678910111213...224225» |
- | Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie
Journal, Real-world evidence, Real-world: Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset. (Pubmed Central) - May 17, 2024
In this large analysis of Australian real-world practice separated by line of therapy, treatment persistence for JAKi was high overall subject to differential follow-up, but declined in later lines. JAKi to JAKi switching was observed across all lines of therapy.
- | Journal: Rheumatoid factor titers, but not Fc fragments, may be strongly associated with drug survival of anti-TNF agents in patients with rheumatoid arthritis. (Pubmed Central) - May 17, 2024
JAKi to JAKi switching was observed across all lines of therapy. Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs.
- ||| Retrospective data, Review, Journal, Adverse events: Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. (Pubmed Central) - May 17, 2024
The OR for VTE for JAK inhibitors compared with TNF inhibitors was 1.28 (0.89-1.84, p<0.01). According to our results, there is no statistically significant difference for MACE or VTE in RA patients who receive either JAK or TNF inhibitors.
- | Remicade (infliximab) / J&J
Journal: Immunotherapy withdrawal by step-down to mesalamine in pediatric patients with ulcerative colitis. (Pubmed Central) - May 17, 2024
We propose that SD to mesalamine can be a reasonable therapeutic consideration for pediatric patients with UC before transitioning to adult gastroenterology care. Shared decision-making is important before such treatment changes.
- || tofacitinib / Generic mfg.
Clinical, Journal: Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. (Pubmed Central) - May 16, 2024
Shared decision-making is important before such treatment changes. In a real-life setting of patients with anti-TNF refractory UC, tofacitinib has proved to be effective in preventing colectomy and inducing clinical and endoscopic remission at 52
- | tofacitinib / Generic mfg.
Journal, Real-world evidence, Real-world: Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience. (Pubmed Central) - May 16, 2024
With high percentage of response in induction treatment, sustained over time, and safe. In the context of severe acute hospitalized UC, it has a role as a potential rescue therapy due to its rapid action.
- ||| Bimzelx (bimekizumab) / UCB
P3 data, Journal: Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies. (Pubmed Central) - May 16, 2024
P3
In the context of severe acute hospitalized UC, it has a role as a potential rescue therapy due to its rapid action. Bimekizumab treatment resulted in rapid and sustained clinically meaningful improvements in disease impact up to 1?year in bDMARD-na
- | methotrexate / Generic mfg.
Journal: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. (Pubmed Central) - May 15, 2024
Bimekizumab treatment resulted in rapid and sustained clinically meaningful improvements in disease impact up to 1?year in bDMARD-na These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.
- || Remicade (infliximab) / J&J
Review, Journal: Management of anal fistulas in Crohn (Pubmed Central) - May 15, 2024
Anal fistulas in Crohn's disease are a real therapeutic challenge. New medical and surgical therapies are currently being evaluated, with promising results.
- || Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
Clinical, Journal, Real-world evidence, Real-world: Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. (Pubmed Central) - May 15, 2024
New medical and surgical therapies are currently being evaluated, with promising results. While no difference in terms of short-term clinical remission was observed, ustekinumab appears to be more effective than vedolizumab to induce endoscopic and histological remission at week 16 after failure of anti-TNFs in UC.
- || Humira (adalimumab) / AbbVie
P1 data, Journal: Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm phase I trial. (Pubmed Central) - May 13, 2024
P1
While no difference in terms of short-term clinical remission was observed, ustekinumab appears to be more effective than vedolizumab to induce endoscopic and histological remission at week 16 after failure of anti-TNFs in UC. This study compared the relative bioavailability of citrate-free high-concentration and reference formulations of the biosimilar adalimumab-adbm (Cyltezo
- || Enbrel (etanercept) / Pfizer, Amgen
Review, Journal: The Role of Etanercept in Controlling Clinical and Radiological Progression in Rheumatoid Arthritis: A Systematic Review. (Pubmed Central) - May 13, 2024
There was also concern about tuberculosis and malignancy, but no recent data is available. Therefore, a larger clinical trial with longer follow-up is required to ascertain long-term safety and benefits.
- | Journal: PANTS extension study: how best to use anti-TNF drugs in Crohn's disease. (Pubmed Central) - May 11, 2024
Therefore, a larger clinical trial with longer follow-up is required to ascertain long-term safety and benefits. No abstract available
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. (Pubmed Central) - May 11, 2024
P=N/A
Low drug concentrations at the end of the induction period predict loss of response by year 3 of treatment, suggesting higher drug concentrations during the first year of treatment, particularly during induction, might lead to better long-term outcomes. Anti-drug antibodies associated with undetectable drug concentrations of infliximab, but not adalimumab, can be predicted by carriage of HLA-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs.
- | Entyvio (vedolizumab) / Takeda
Journal: Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial. (Pubmed Central) - May 11, 2024
However, it may increase fecal calprotectin, histologic and histo-endoscopic activity. Histological activity and prior anti-TNF exposure may predict disease relapse upon thiopurine withdrawal for patients using vedolizumab for UC; Australian and New Zealand Trial Registry, number ACTRN12618000812291.
- | Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Journal, Real-world evidence, Real-world: Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study. (Pubmed Central) - May 11, 2024
This is the first real-life study to report long-term outcomes in patients with refractory CD treated with risankizumab. Half of the patients achieved steroid-free clinical remission after one year, and the safety profile was consistent with the literature.
- || Clinical, Observational data, Journal: Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. (Pubmed Central) - May 10, 2024
Half of the patients achieved steroid-free clinical remission after one year, and the safety profile was consistent with the literature. JAKis showed the lowest drug retention due to AE in patients with moderate-to-severe and severe renal impairment (eGFR?<?45
- | Journal: Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. (Pubmed Central) - May 10, 2024
JAKis showed the lowest drug retention due to AE in patients with moderate-to-severe and severe renal impairment (eGFR?<?45 Eleven clinical trials enrolling 5450 UC patients (infliximab
- Remicade (infliximab) / J&J
Perception of Pediatric Gastrointestinal Specialists on Anti -tumor Necrosis Factor Therapy in Patients with Pediatric Crohn's Disease (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_344;
Regarding the selection between infliximab and adalimumab, the main factors affecting decisions were disease severity of the patient (40.5%), preference of the patient (23.8%), quick resolution of clinical symptoms and laboratory results (21.4%), and injection route and intervals of the drugs (14.3%)...Conclusion : The majority of pediatric GI specialists considered an upfront or accelerated step-up approach as the appropriate treatment strategy for pediatric CD. The Korean national insurance policy should be able to support the perception of Korean pediatric GI specialists
- Remicade (infliximab) / J&J, Humira SC (adalimumab/hyaluronidase) / AbbVie
Factors Contributing to the PREFERence of Pediatric Patients with Inflammatory Bowel Disease in Selecting an Anti -tumor Necrosis Factor Agent (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_313;
Background / Aim : Treatment with anti-TNF agents, such as intravenous infliximab (IFX) and subcutaneous adalimumab (ADL), has increased in pediatric inflammatory bowel disease (IBD). Conclusion : Anti-TNF na
- Identification of Specific Cell Subsets Related to Treatment Response after Anti - tumor Necrosis Factor Use in Korean Ulcerative Colitis Patients using Single Cell RNA Sequencing: A Preliminary Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_307;
This signifies a change in the composition of this specific cell cluster post-anti-TNF treatment and suggests a potential restoration of this cell cluster's proportion towards a healthier state (Figure 1). Conclusion : In Korean UC patients, this data is crucial for understanding the impact of anti-TNF treatment on the cellular composition or behavior of the stem cell-like cluster, suggesting potential effect of anti-TNF treatment on this particular cell population.
- The Timing of Anti -TNF Therapy Initiation has Different Impacts depending on the Type of Inflammatory Bowel Disease (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_293;
Conclusion : This study highlights the complexity in IBD management, emphasizing that the impact of anit-TNF therapy initiation timing varies between UC and CD. It underscores the need for personalized treatment strategies, considering the IBD type, patient-specific factors, and possible interactions with other medications.
- Factors associated with Time -to-perianal Surgery after Diagnosis in Paediatric Patients with Crohn's Disease (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_290;
Conclusion : Among the factors associated with time-to-perianal surgery after diagnosis, anti-TNF agent usage was the only modifiable factor. Upfront anti-TNF agent usage may lower the incidence of perianal surgery after diagnosis in pediatric patients with CD.
- Comparative Real -world Outcomes between Ustekinumab, Infliximab, and Adalimumab in Bio -nave and Bio -experienced Crohn's Disease Patients: A Retrospective Multicenter Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_286;
In bio-experienced CD patients, with 35 in the UST group and 13 in the anti-TNF agents group, the UST group showed a lower risk of drug discontinuation (P = 0.004) than the anti-TNF agents group. Conclusion : This study suggests that UST, IFX, and ADA are equally effective in bio-na
- Stelara (ustekinumab) / J&J
Superior Treatment Persistence with Ustekinumab in Biologic -Experienced Crohn's Disease: Real -world Registry Data from the Persistence Australian National IBD Cohort (PANIC) Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_275;
Per line of therapy, 915/2,029 (45.1%) patients used adalimumab, 722/2,029 (35.6%) used infliximab, 155/2,029 (7.6%) used vedolizumab, and 237/2,029 (11.7%) used ustekinumab. Conclusion : This large national prospective database with non-hierarchical prescribing of biological agents did not identify superior persistence of any agent in bio-na
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
Persistence Comparison of Ustekinumab and Anti -TNF Agents in Vedolizumab - Experienced IBD Patients: A Retrospective Cohort Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_273;
UST required more dose escalations, but safety profiles of both treatments were comparable. Conclusion : UST shows superior one-year persistence over anti-TNF in VDZ-experienced Crohn's disease patients, although with a higher need for dose escalation
- Zeposia (ozanimod) / BMS
Long -term Clinical and Endoscopic Outcomes in True No rth Week 52 Clinical Remitters o ver 3 Years of Treatment with Ozanimod: An Interim Analysis of the True North Open -label Extension Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_263;
Conclusion : Most patients who achieved clinical remission after 1 year of OZA had sustained efficacy for an additional 2 years. These findings provide further evidence for the long-term durability of OZA treatment in patients with moderate to severe UC
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Stelara (ustekinumab) / J&J
Risankizumab versus Ustekinumab for Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3b SEQUENCE Study (Studio 8-9 (6F)) - May 10, 2024 - Abstract #IMKASID2024IMKASID_262;
Conclusion : In pts with moderate to severe CD who failed anti-TNF therapy, RZB demonstrated non-inferiority to UST in achieving wk24 clinical remission, superiority in achieving wk48 endoscopic remission, and superiority for achieving all secondary endpoints. The safety profiles of RZB and UST were consistent with previously published results.
- | Journal: Children with Localized Crohn's Disease Benefit from Early Ileocecal Resection and Perioperative Anti-Tumor Necrosis Factor Therapy. (Pubmed Central) - May 7, 2024
For relevant catch-up growth an earlier intervention is necessary. Continuous perioperative anti-TNF therapy had no increased risk of perioperative infections.
- | Journal: Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study. (Pubmed Central) - May 7, 2024
P=N/A
A reduction in inflammation was not associated with improved MFR. However, a modest reduction in interleukin-1b and no other inflammatory pathways was correlated with a reduction in subclinical myocardial injury.
- | Stelara (ustekinumab) / J&J
Retrospective data, Journal: Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study. (Pubmed Central) - May 7, 2024
This study highlights the safety and effectiveness of UST as an induction and maintenance therapy for UC. Chronic continuous type and previous anti-TNF and VDZ exposure negatively contributed to short-term effectiveness, whereas short-term effectiveness provided good persistency.
- || Retrospective data, Review, Journal, Metastases: Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. (Pubmed Central) - May 7, 2024
Chronic continuous type and previous anti-TNF and VDZ exposure negatively contributed to short-term effectiveness, whereas short-term effectiveness provided good persistency. This meta-analysis highlights the superior persistence of ustekinumab and vedolizumab over TNFi, and offers valuable insights for clinicians navigating the challenging landscape of UC and CD therapeutic choices.
- | Journal: Gut microbiome and metabolome to discover pathogenic bacteria and probiotics in ankylosing spondylitis. (Pubmed Central) - May 7, 2024
Through experimental studies, the relationship between microbes and metabolites was further confirmed, and the impact of these two types of microbes on the enterocytes and the inflammatory cytokine interleukin-18 (IL-18) was explored. In summary, multi-omics exploration elucidated the impact of TNFi on the gut microbiota and metabolites and proposed a novel therapeutic perspective: supplementation of compounds to inhibit potential pathogenic bacteria and to promote potential probiotics, therefore controlling inflammation in AS.
- || tofacitinib / Generic mfg.
Review, Journal: Impact of Biologics and Small Molecule Agents on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review. (Pubmed Central) - May 6, 2024
There is a need for further perioperative data for other agents. See video from symposium .
- | Journal: The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug. (Pubmed Central) - May 3, 2024
There was no cognitive decline in participants with MCI being treated with TNFis and csDMARDs, raising the possibility both classes of drug may be protective. Future studies should consider whether controlling inflammatory diseases using any approach is more important than a specific therapeutic intervention.
- | Humira (adalimumab) / AbbVie
Journal: Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort?study. (Pubmed Central) - May 3, 2024
In this nationwide cohort study, the rates of GIP did not differ between groups of patients initiating JAKi and adalimumab treatment. These results need to be confirmed in other observational studies.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Biomarker, Journal: Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease. (Pubmed Central) - May 3, 2024
Anti-TNF exposure-response relationship may be different in pIBD versus aIBD. No biomarkers for maintained response were identified, but 9 inflammatory proteins were of interest as potential predictors for loss of response in pIBD.
- | Journal: Biallelic human SHARPIN loss of function induces autoinflammation and immunodeficiency. (Pubmed Central) - May 2, 2024
Treatment of one SHARPIN-deficient individual with anti-TNF therapies led to complete clinical and transcriptomic resolution of autoinflammation. These findings underscore the critical function of the LUBAC as a gatekeeper for cell death-mediated immune dysregulation in humans.
- | Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis. (Pubmed Central) - May 2, 2024
UST and VDZ are similarly effective for inducing clinical remission in anti-TNF refractory UC in pediatric patients. Providers should consider safety, tolerability, cost, and comorbidities when deciding between these therapies.
- || Bimzelx (bimekizumab) / UCB
Retrospective data, Review, Journal: Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. (Pubmed Central) - May 2, 2024
Providers should consider safety, tolerability, cost, and comorbidities when deciding between these therapies. Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-na
- | Journal: Transcriptomic network analysis reveals key drivers of response to anti-TNF biologics in patients with rheumatoid arthritis. (Pubmed Central) - May 2, 2024
Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-na This study provides response-specific treatment-induced transcriptomic signatures by comparing the transcriptomic landscape between patients with excellent and null responses to anti-TNF drugs at both gene and network levels.
- || tofacitinib / Generic mfg.
Clinical data, Review, Journal: Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data. (Pubmed Central) - May 2, 2024
P1, P2, P2
This study provides response-specific treatment-induced transcriptomic signatures by comparing the transcriptomic landscape between patients with excellent and null responses to anti-TNF drugs at both gene and network levels. Accordingly, it is appropriate to use a precautionary approach and extrapolate differentiating risk factors identified from ORAL Surveillance (age???65
- | hydroxychloroquine / Generic mfg.
Retrospective data, Journal, Real-world evidence, Real-world: Real-world pharmacological treatment of pregnant patients with rheumatic diseases from China: a retrospective analysis from 2016 to 2021. (Pubmed Central) - May 2, 2024
Conventional therapeutic drugs, especially glucocorticoids, LMWHs, and hydroxychloroquine were the most widely used drugs in pregnant patients with rheumatic diseases. However, IVIG and TNFi, relatively high cost, have shown gradual increases in clinical use since 2019.
- | Humira (adalimumab) / AbbVie
Journal: Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis. (Pubmed Central) - May 2, 2024
History of interruption in anti-TNF therapy and flare during adalimumab were associated with development of AAA, while weekly dosing of adalimumab was protective against AAA. Identification of those with higher risk of developing AAA may guide in clinical decision making to optimize management for these patients.
- | tofacitinib / Generic mfg.
Journal: Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results from the CorEvitas Rheumatoid Arthritis Registry. (Pubmed Central) - May 1, 2024
P=N/A
TOF effectiveness (CDAI LDA) was observed in a US real-world setting of patients with RA regardless of TOF regimen, line of therapy, time of initiation, and dose. (ClinicalTrials.gov: NCT04721808).
- | Retrospective data, Journal: Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with biologic or targeted therapies: a meta-analysis of randomized controlled trials. (Pubmed Central) - May 1, 2024
(ClinicalTrials.gov: NCT04721808). In contrast to serious infections, the risk of global infections is moderately increased with b/tsDMARDs in spondyloarthritis, and is associated in particular with use of TNF and IL-17 inhibitors.
- | Journal: Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis? (Pubmed Central) - May 1, 2024
In contrast to serious infections, the risk of global infections is moderately increased with b/tsDMARDs in spondyloarthritis, and is associated in particular with use of TNF and IL-17 inhibitors. No abstract available
- | Journal: Weight loss affects disease activity and treatment response in inflammatory rheumatic diseases. (Pubmed Central) - May 1, 2024
Screening and management of obesity are part of the dietary recommendations of the French Society for Rheumatology in patients with chronic inflammatory rheumatic diseases. Of course, this should be combined with others lifestyle modifications such as smoking cessation, higher food quality, increased physical activity and reduced sedentary behavior.
- || Review, Journal: Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings). (Pubmed Central) - May 1, 2024
Tapering of TNF inhibitors may be feasible in certain axSpA patients with an acceptable disease state; however, discontinuation is not currently recommended owing to increased risk of flare. Future studies with axSpA patients with longer remission duration prior to taper and different doses and types of b-DMARDs may provide more guidance.
- Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
EFFICACY AND DRUG SURVIVAL OF BIOLOGIC AGENTS IN BEHCET'S DISEASE: A REAL-LIFE OBSERVATIONAL MONOCENTRIC STUDY (Station 08) - May 1, 2024 - Abstract #AUTO2024AUTO_266;
The aim is to assess their effectiveness and 10-year retention rate.Methods We included patients treated with Infliximab (IFX), Adalimumab (ADA), Apremilast (APR), and Tocilizumab (TCZ) between 2009-2023...Previous administration of colchicine was more frequent in patients treated with APR (p=0.035)...Daily prednisone dose was significantly reduced with IFX (10[5-21.25]vs5[0-10],p=0.015), while no differences were noted in acute phase reactants...Discontinuation of bDMARDs was due to intolerance (3.7%), remission (3.7%) and adverse events (15.1%). conclusions :bDMARDs treatment is effective and its retention rate is affected by female sex, but not by concomitant cDMARDs.